- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05970978
A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
January 10, 2024 updated by: Innovent Biologics (Suzhou) Co. Ltd.
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112
This is a multicenter, open-label study aim to evaluate the efficacy and safety of IBI112 in Chinese participants with plaque psoriasis who were treated with biologics and switched to IBI112.
The study will enroll 160 participants who were diagnosed with plaque psoriasis.
The whole study consists of 4 weeks of screening, 32 or 36 weeks of treatment and a safety follow-up visit at Week 44.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
160
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aoling Chen
- Phone Number: 15950023301
- Email: aoling.chen@innoventbio.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Recruiting
- Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology)
-
Contact:
- Furen Zhang
- Phone Number: 13608921718
- Email: ZhangFuRenlcsy@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18 to 75 years old;
- Evaluated suitable for continuing biologic therapy for plaque psoriasis by the investigator;
- Received previous biologic therapy with at least 4 months.
Exclusion Criteria:
- Diagnosed with guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, or drug-induced psoriasis (e.g., psoriasis caused by beta blockers, calcium channel inhibitors, etc.) at screening;
- Previously treated with IBI112 or other IL-23 inhibitors;
- Treated with two biologics for psoriasis within 4 months prior to screening;
- Treated with topical therapy for psoriasis within 2 weeks prior to the first dose administration, or treated with systemic non-biological agents or phototherapy within 4 weeks prior to the first dose administration;
- Treated with Natalizumab, or B/T cell regulators (e.g., Rituximab, Abatacept, or Visilizumab) within 12 months prior to the first dose administration;
- Not willing to avoid constant sunshine and other ultraviolet light sources exposure during the study;
- Treated with an investigational biologic within 6 months prior to the first dose administration, or any investigational therapy within 30 days, or an investigational drug within 5 half-lives, or currently participating in a clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Response to previous biologic therapy
Participants with sPGA0 or 1 score and the body surface area affected with psoriasis lesions <3% at baseline; or PASI-75 was achieved after treated with the previous biologics.
200mg of IBI112 will be administered subcutaneously at week 0, 12, 24 and 36.
|
IBI112 200mg s.c. at week 0, 12, 24 and 36.
Other Names:
|
Experimental: Poor response to previous biologic therapy
Participants with sPGA score ≥2 at baseline, or body surface area affected with psoriasis lesions ≥3% at baseline, o PASI-75 was not reached after treated with previous biologics.
200mg of IBI112 will be administered subcutaneously at week 0, 4, 8, 20 and 32.
|
IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants who achieve sPGA clean (0) or nearly clean (1) ,and BSA < 3%
Time Frame: Week 16
|
Week 16
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants who achieve sPGA clean (0) at Week 16.
Time Frame: Week 16
|
Week 16
|
Percentage of participants with a DLQI score of 0/1 at Week 16.
Time Frame: Week 16
|
Week 16
|
Percentage of participants with sPGA 0/1 or sPGA 0 or DLQI 0/1 at Week 44.
Time Frame: Week 44
|
Week 44
|
Percentage of participants who achieve sPGA 0 or 1 at week 16 and maintain that up to Week 44
Time Frame: Week 16 up to Week 44
|
Week 16 up to Week 44
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 28, 2023
Primary Completion (Estimated)
September 30, 2024
Study Completion (Estimated)
February 28, 2025
Study Registration Dates
First Submitted
July 24, 2023
First Submitted That Met QC Criteria
July 24, 2023
First Posted (Actual)
August 2, 2023
Study Record Updates
Last Update Posted (Actual)
January 12, 2024
Last Update Submitted That Met QC Criteria
January 10, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIBI112A202CN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on regular treatment
-
Shanghai University of Traditional Chinese MedicineUnknown
-
Shanghai Tongji Hospital, Tongji University School...Huashan Hospital; Puer Hospital of Chinese Medicine; Dangyang Hospital of Chinese... and other collaboratorsRecruiting
-
Shanghai Tongji Hospital, Tongji University School...Department of Emergence, The First Hospital Affiliated to South China University... and other collaboratorsUnknownMorality | Predictive Model | Risk Factor, SepsisChina
-
Jakub HadzikWrocław Medical University; Dentsply Sirona Implants and ConsumablesCompletedPartial Edentulism | Tooth Loss
-
Grupo LusófonaUniversity of Lisbon; Fundação para a Ciência e a TecnologiaCompletedObesity | Physical Activity | Sedentary LifestylePortugal
-
Capital Medical UniversityWeihai Municipal Hospital; Heze Municipal Hospital; The Sixth People's Hosptial...Completed
-
GenMont Biotech IncorporationChang Gung Memorial HospitalWithdrawnAlzheimer Disease
-
CHU de ReimsPneumRx, Inc.Unknown
-
University of ValenciaCompletedTemporomandibular Dysfunction (TMD)Spain
-
Portsmouth Hospitals NHS TrustBritish Lung Foundation; University of OxfordCompletedMesothelioma, MalignantUnited Kingdom, Australia